Added Value of O-RADS in Evaluation of Ovarian Lesions

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04579575
Collaborator
(none)
30
9.4

Study Details

Study Description

Brief Summary

To detect added value of O-RADS in evaluation of ovarian lesions and compare O-RADS with GI-RADS regarding malignancy rate, the validity and reliability through pathological results and other modalities

Condition or Disease Intervention/Treatment Phase
  • Device: Trans-abdominal Ultrasound

Detailed Description

Ultrasound (US) continues to be the initial imaging modality of choice for the identification and characterization of adnexal masses (AM) . Structured reporting of AM findings was identified by a Society of Radiologists in Ultrasound consensus working group as a target for the investigation to improve the management of women with AM .

Many established guidelines and structured reporting have been developed using sonography to characterize AM, including subjective assessment, simple scoring systems, and statistically derived scoring systems .

In 2008, the International Ovarian Tumor Analysis (IOTA) group proposed the use of US simple rules for the diagnosis of ovarian malignancy. These are based on a set of five US features indicative for a benign tumor (B features), and five US features indicative for a malignant tumor (M features)

. In 2009, the Gynecology Imaging Reporting and Data System (GI-RADS) was designed as an attempt allowing standardized reporting of AM. This system is based on recognition patterns and criteria provided by the IOTA.

The American College of Radiology (ACR) published the Ovarian-Adnexal Reporting and Data System (O-RADS), which provides an up-to-date suggestion to stratify the AM according to sonographic features. The O-RADS offers a comprehensive algorithm that categorizes AM by their possibility of being normal (O-RADS 1), to high risk of malignancy (O-RADS 5) .

For the application of the US classification system of AM in clinical settings, it is essential to evaluate their validity and reproducibility. Several studies have investigated the validity of these risk stratification systems in the assessment of AM. However, data on the comparability and reproducibility of the systems are limited.

The purpose of this study is To detect added value of O-RADS in evaluation of ovarian lesions and compare O-RADS with GI-RADS regarding malignancy rate , the validity and reliability through pathological results.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Added Value of Ovarian-Adnexal Reporting and Data System in Evaluation of Ovarian Lesions
Anticipated Study Start Date :
Dec 20, 2021
Anticipated Primary Completion Date :
Jan 1, 2022
Anticipated Study Completion Date :
Oct 1, 2022

Outcome Measures

Primary Outcome Measures

  1. Added value of Ovarian-Adnexal Reporting and Data System in evaluation of 30 participants with ovarian lesions regarding malignancy rate ,the validity and reliability after comparison with pathology specimens results . [Baseline]

    Evaluation of the ovarian lesions by Trans-abdominal and Trans-vaginal Ultrasound for diagnosis of ovarian malignancy as early as possible for further management

Eligibility Criteria

Criteria

Ages Eligible for Study:
17 Years to 75 Years
Sexes Eligible for Study:
Female
Inclusion Criteria:
  • All newly diagnosed patients with ovarian lesions referred to the radiology department.

  • Must be able to be examined.

Exclusion Criteria:
  • Patients younger than 17 years old

  • Patient who refused to be a part of the study and undergo examination.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

  • Study Director: Hisham Moustafa Kamel, Assiut University
  • Study Director: Haisam Ahmed Samy Aly Atta, South Egypt Cancer Institute ,Assiut University
  • Study Director: Doaa Mohamed Fouad, South Egypt Cancer Institute ,Assiut University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Mahmoud Abdel Maged Mohamed, Principal investigator, Assiut University
ClinicalTrials.gov Identifier:
NCT04579575
Other Study ID Numbers:
  • O-RADS value in ovarian lesion
First Posted:
Oct 8, 2020
Last Update Posted:
Dec 16, 2021
Last Verified:
Dec 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 16, 2021